Abstract
Stevens-Johnson syndrome (SJS) is an uncommon life-threatening skin disease, generally induced by drugs. Extracutaneous manifestations of the syndrome can occur, and may involve the conjunctiva, buccal mucosa, gastrointestinal and genitourinary tracts. Cholestatic hepatitis has been rarely described in SJS.
A 29-year-old woman was admitted with generalized cutaneous eruption. A self-medication with paracetamol had been started three days earlier. Clinical signs and skin biopsy were consistent with SJS. Five days later, the patient developed jaundice. Serial liver function tests showed rising transaminases, bilirubin, alkaline phosphatase and γ-glutamyl transferase. Liver biopsy was performed and was consistent with the diagnosis of drug-induced cholestatic hepatitis. Adequate supportive care was provided to the patient. Skin lesions disappeared within two weeks. Jaundice disappeared progressively, and liver tests returned to normal.
Herein, we report the first case of SJS associated with cholestatic hepatitis after ingestion of therapeutic doses of paracetamol.
Keywords: Cholestasis, drug-induced, eruption, hepatitis, paracetamol, Stevens-Johnson syndrome.
Current Drug Safety
Title:Paracetamol-Induced Stevens Johnson Syndrome and Cholestatic Hepatitis
Volume: 10 Issue: 2
Author(s): Raoudha Slim, Neila Fathallah, Amina Aounallah, Mehdi Ksiaa, Badreddine Sriha, Rafiaa Nouira and Chaker Ben Salem
Affiliation:
Keywords: Cholestasis, drug-induced, eruption, hepatitis, paracetamol, Stevens-Johnson syndrome.
Abstract: Stevens-Johnson syndrome (SJS) is an uncommon life-threatening skin disease, generally induced by drugs. Extracutaneous manifestations of the syndrome can occur, and may involve the conjunctiva, buccal mucosa, gastrointestinal and genitourinary tracts. Cholestatic hepatitis has been rarely described in SJS.
A 29-year-old woman was admitted with generalized cutaneous eruption. A self-medication with paracetamol had been started three days earlier. Clinical signs and skin biopsy were consistent with SJS. Five days later, the patient developed jaundice. Serial liver function tests showed rising transaminases, bilirubin, alkaline phosphatase and γ-glutamyl transferase. Liver biopsy was performed and was consistent with the diagnosis of drug-induced cholestatic hepatitis. Adequate supportive care was provided to the patient. Skin lesions disappeared within two weeks. Jaundice disappeared progressively, and liver tests returned to normal.
Herein, we report the first case of SJS associated with cholestatic hepatitis after ingestion of therapeutic doses of paracetamol.
Export Options
About this article
Cite this article as:
Slim Raoudha, Fathallah Neila, Aounallah Amina, Ksiaa Mehdi, Sriha Badreddine, Nouira Rafiaa and Salem Ben Chaker, Paracetamol-Induced Stevens Johnson Syndrome and Cholestatic Hepatitis, Current Drug Safety 2015; 10 (2) . https://dx.doi.org/10.2174/1574886309666140827122735
DOI https://dx.doi.org/10.2174/1574886309666140827122735 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Biological Evaluation of New imidazo[1,2-a]pyridine Derivatives as Selective COX-2 Inhibitors
Letters in Drug Design & Discovery Hurdles in the Drug Discovery of Cathepsin K Inhibitors
Current Topics in Medicinal Chemistry Recent Advances in Vaginal Delivery for the Treatment of Vulvovaginal Candidiasis
Current Molecular Pharmacology Coenzyme Q10: A Potential Adjunct for Treatment of Antiphospholipid Syndrome and Recurrent Miscarriage
Current Immunology Reviews (Discontinued) Anti-Selectin Therapy for the Treatment of Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) siRNA Delivery with Lipid-based Systems: Promises and Pitfalls
Current Topics in Medicinal Chemistry Plasma Cytokine Levels in Overweight Versus Obese Disease-Free Perimenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Protease-Activated Receptors (PARs) are Partly Pro-Inflammatory and Partly Anti-Inflammatory: Will PAR Agonists or Antagonists Participate in Future Drug Therapies?
Current Drug Targets Dry Eye Disease: Present Challenges in the Management and Future Trends
Current Pharmaceutical Design Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Potential of Nanocarriers in Genetic Immunization
Recent Patents on Drug Delivery & Formulation Investigation of the Roles of New Antiepileptic Drugs and Serum BDNF Levels in Efficacy and Safety Monitoring and Quality of Life: A Clinical Research
Current Clinical Pharmacology Responses of Glial Cells to Stress and Glucocorticoids
Current Immunology Reviews (Discontinued) Effects of Agkistrodon halys Metalloproteinase in vitro and in vivo
Current Chemical Biology Actions of Alcohol in Brain: Genetics, Metabolomics, GABA Receptors, Proteomics and Glutamate Transporter GLAST/EAAT1
Current Molecular Pharmacology In Silico Prediction of Hepatotoxicity
Current Computer-Aided Drug Design Clozapine Safety, 40 Years Later
Current Drug Safety Characterizing Protein Structure, Dynamics and Conformation in Lyophilized Solids
Current Pharmaceutical Design Lactobacillus rhamnosus GG Influences Polyamine Metabolism in HGC-27 Gastric Cancer Cell Line: A Strategy Toward Nutritional Approach to Chemoprevention of Gastric Cancer
Current Pharmaceutical Design Synthesis and Biological Activity of Prostaglandin Analogs Containing Heteroatoms in the Cyclopentane Ring
Current Organic Chemistry